Figure 5.

Intratumoral AdCMVdelta24 treatment augments intravenously transferred OT1 cell therapy. (A–D) C57BL/6 mice bearing 5 d intracranial GL261glioma were injected intratumorally with AdCMVdelta24 virus or control PBS. Flow cytometry analysis of CD8⁺ T cells, IFNγ⁺ CD8⁺T cells isolated from brains and cervical lymph nodes (cLNs) were performed at 72 h and 1 week after viral treatment. (A–B) Frequency of CD8⁺IFNγ⁺ T cells in cLNs (A) or in brains (B) at 72 h post treatment. (C–D) Total number of CD8⁺T cells (C) and IFNγ⁺CD8⁺ T cells (D) in brains at one week after viral treatment. (E) Tumor sections from brain at one week after viral treatment, stained for CD8⁺ T cells and imaged under confocal microscope (Top panel, PBS treatment; Bottom panel, AdCMVdelta24 treatment). (F–G) C57BL/6 mice (n = 5) were intracranially injected with GL261-OVA cells at 1 × 10⁵ in 5 uL of PBS (d0). Five days later (d5), AdCMVdelta24 was intratumorally injected, followed by 1 × 10⁶ OT1 cells infusion through either tail vein (i.v) (F) or intratumoral (i.t.) injection (G) at 72 h post viral treatment. Mice were then monitored for survival. *p < 0.05, and n.s., not significant (log-rank test).